Jim Cramer's Stop Trading: Does Agios Pharmaceuticals Have a Monumental Cancer Treatment?

NEW YORK (TheStreet) -- Agios Pharmaceuticals (AGIO) may have one of the first big breaks in cancer treatment that doesn't involve chemotherapy, according to TheStreet's Jim Cramer. 

Must Read: 10 Stocks Carl Icahn Loves in 2014

On CNBC's "Cramer's Stop Trading" segment, the co-manager of the Action Alerts PLUS portfolio said November seems too early for the company to reveal its results for Phase 1 testing of the drug, AG-120.

It seems too early, unless of course, the company has something that is going to be monumental in the future, Cramer added. 

He noted that Celgene (CELG) has the marketing rights to the drug and also a large stake in Agios Pharmaceuticals.

Must Read: Biotech Stock Mailbag: ProQR, Vertex Pharma, Tekmira, Agios


-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract

Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract

4 Health Care Charts Signaling Buys: Pfizer, Amgen Included

4 Health Care Charts Signaling Buys: Pfizer, Amgen Included

These 4 Healthcare Charts Are Signaling Buys

These 4 Healthcare Charts Are Signaling Buys

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Analysts' Actions -- Chipotle, Disney, Brinker, JPMorgan and More

Analysts' Actions -- Chipotle, Disney, Brinker, JPMorgan and More